Archive for April, 2019

Lyme Disease Lecture Notes: Microbiologist Tom Grier

https://www.dropbox.com/s/vzfjqiytt8bej28/LD%20Lecture%20Handout%20Big%204_19%20%2011_13_18.pdf?

Lyme disease Lecture notes

created by Microbiologist Tom Grier

These notes (in top link) are very helpful, informative, and cover a lot of ground, from what Lyme is, to problems with testing, to patents owned by the CDC, to myths about Lyme, to the plethora of research that proves its persistence, and much, much more.  

For more on Grier’s work:  https://madisonarealymesupportgroup.com/2016/12/19/microbiologist-tom-grier/

https://madisonarealymesupportgroup.com/2011/09/21/lab-tests-for-lyme-disease-by-tom-grier/

Lyme on the Brain, part 1:  https://madisonarealymesupportgroup.com/2010/08/09/tom-grier-lyme-lecture-outline/

Lyme on the Brain, part 2:  https://madisonarealymesupportgroup.com/2010/08/18/lyme-on-the-brain-part-2-by-tom-grier/

Lyme on the Brain, part 3:  https://madisonarealymesupportgroup.com/2010/08/29/lyme-on-the-brain-by-tom-grier-part-3-b-lecture-notes/

Lyme on the Brain, part 4:  https://madisonarealymesupportgroup.com/2010/08/30/lyme-on-the-brain-by-tom-grier-part-4-lecture-notes/

Listen to Dr. Alan MacDonald and Tom Grier in radio interview:  https://kpfa.org/episode/99572/

 

S.O.S. Documentary

SOS Lyme Trailer

By

PRESS RELEASE – LAUNCH OF NEW LYME DOCUMENTARY

Lyme disease is a terrible disease and also the fastest growing epidemic in the world; difficult to detect and treat. Too little money, treatment options and social attention ensure that patients are left to their own devices. To denounce this, a group of Lyme patients is campaigning for the SOS Lyme Epidemic .On the eve of the Week of Tick 2019, a new Lyme documentary – which patients have made themselves- will be launched SOS, “an invisible epidemic” by director Pim Giel.Lyme disease is an infectious disease with a greater impact than we all think. The WHO even speaks of a new epidemic. International experts are now successful with a new international guideline (ILADS) for the treatment of chronic Lyme disease. But this is hardly recognized in the Netherlands and Belgium by politics, science and health insurers. As a result, patients are deprived of treatment, care and other facilities; in fact, they are left to their own devices. Only patients with sufficient personal money can go abroad for this. Patients themselves often have no money (anymore) for a treatment and are becoming increasingly ill. Sometimes resulting in death or euthanasia.

CAMPAIGN LYME PATIENTS FOR RECOGNITION OF CHRONIC LYME DISEASE

In the Netherlands and Belgium, a group of thousands of Lyme patients are taking action to ask the general public for attention and recognition for the dire situation they are in. With the (media) campaign SOS Lyme Epidemic , they are fighting for a breakthrough in the deadlock of treatment of chronic Lyme disease and for breaking the injustice. Various benefit campaigns and the petition https://iladsvoorlyme.petities.nl are part of this campaign, which is supported by ambassadors and former Lyme patient actor Miro Kloosterman, rapper / singer Pete Philly and in Belgium politician John Crombez and presenter Roos van de Acker .The patients are working hard – with the help of Nicolette van Dam, among others – to collect the necessary 40,000 signatures to present to parliament in May – the Lyme awareness month.

DOCUMENTARY SOS LYME, ‘AN INVISIBLE EPIDEMIC’

The patients, in collaboration with Stichting Happy Motion, have made the documentary SOS Lyme, ‘an invisible epidemic’ with the aim of distributing it internationally. The film by director Pim Giel discusses the severity of Lyme disease such as paralysis, pain, spasms, but also about the consequences such as, out-of-home placement, alleged child abuse, euthanasia, benefit issues and misdiagnosis. Not only patients with chronic Lyme are in the video, but also international specialists like Dr. Richard Horowitz (USA), Dr. Armin Schwarzbach (DE), Prof. Dr. de Meirleir (BE), Dr. Burrascano (USA), Dr. Klinghardt (US) as well as experts from the Netherlands.

The documentary is the heart of the Lyme Patients campaign: “In this documentary we want to show what it’s like to live as a patient with this misunderstood and terrible disease,” said campaign leader Daisy. “It is a film about injustice, struggle and conflicting interests.”

FILM SCREENINGS AND LYME GATHERINGS IN THE COUNTRY

The documentary will be made accessible to a wide audience through the website and can be seen at various Lyme meetings that will be organized in the country. With a crowdfunding campaign the Lyme patients try to support the creation of the film and their campaign.

Note for editors
For more information, interviews (with campaign leader Daisy, filmmaker Pim Giel), photo materials, etc., please contact Bastiaan Piloo, producer b.piloo@happymotion.org +31(0)6 – 11 621 411

For more information, visit

About the Happy Motion Foundation
With documentaries, digital media, events and education, the foundation brings serious themes to the attention of a wide audience in a positive way. In this way it wants to give vulnerable groups in our society the recognition and support they deserve. www.happymotion.org

Go here to support & watch the documentary:  https://www.lymeepidemie.nl/documentary/?lang=en

 

 

 

Bio-Rad Receives FDA Clearance For Lyme Total Assay

http://www.bio-rad.com/en-us/corporate/newsroom/bio-rad-announces-innovative-test-aid-diagnosis-lyme-disease-with-fda-clearance-bioplex-2200-lyme-total-assay?ID=Bio-Rad-Announces-In_1554223890

Bio-Rad Announces Innovative Test to Aid in the Diagnosis of Lyme Disease with the FDA Clearance of the BioPlex 2200 Lyme Total Assay

Date: 04/02/2019

HERCULES, Calif.–Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its BioPlex 2200 Lyme Total Assay, an innovative multiplex test method to aid in the diagnosis of Lyme disease.

Lyme disease is the most common tick-borne illness in the United States. Many signs and symptoms of the disease are similar to other conditions so diagnosis can be challenging; however, individuals immediately treated for the disease usually recover rapidly and completely. The BioPlex 2200 Lyme Total Assay can simultaneously detect multiple targets, providing laboratories valuable information in the early stages of Lyme disease so patients are able to receive treatment as quickly as possible.

“The addition of the BioPlex 2200 Lyme Total assay broadens our BioPlex 2200 System infectious disease menu, offering laboratories the ability to detect Lyme disease at an early stage and thus fulfilling an important medical need in the management of Lyme disease,” said John Hertia, Bio-Rad President, Clinical Diagnostics Group.

The release of the BioPlex 2200 Lyme Total assay is the latest offering in Bio-Rad’s infectious disease menu for the BioPlex 2200 System, an automated multiplex technology platform. The BioPlex 2200 System provides clinical laboratories the capability to rapidly process or “multiplex” multiple individual tests that are traditionally processed separately, conserving patient sample volume and simplifying workflow.

Bio-Plex and Bio-Rad are trademarks of Bio-Rad Laboratories, Inc. in certain jurisdictions

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global leader in developing, manufacturing, and marketing a broad range of innovative products for the life science research and clinical diagnostic markets. With a focus on quality and customer service for over 65 years, our products advance the discovery process and improve healthcare. Our customers are university and research institutions, hospitals, public health and commercial laboratories, biotechnology, pharmaceutical, as well as applied laboratories that include food safety and environmental quality. Founded in 1952, Bio-Rad is based in Hercules, California, and has a global network of operations with more than 8,000 employees worldwide. Bio-Rad had revenues exceeding $2.2 billion in 2018. For more information, please visit www.bio-rad.com.

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding our expectations regarding our products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as “will”, “believe,” “expect,” “anticipate,” “may,” “plan,” “intend,” “estimate,” “offers,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” in Bio-Rad’s public reports filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.

Press Contact:
Bio-Rad Laboratories, Inc.
Tina Cuccia, Corporate Communications
510-724-7000
tina_cuccia@bio-rad.com

 

 

Breaking News: Definition of Lyme Disease Dementia Has Improved

https://www.linkedin.com/pulse/breaking-news-definition-lyme-disease-dementia-has-jenna-luche-thayer/

BREAKING NEWS: Definition of Lyme disease Dementia has improved

Jenna Luche-Thayer
Dementia is a rapidly expanding and fatal neuro degenerative illness that may affect all persons. Usually it effects the elderly.  Implications and challenges regarding the new definition follow.
Lyme is a bacterial infection
Both Lyme Borreliosis and relapsing fever borreliosis have stages of dissemination and multiple varieties of symptoms afflicting multiple bodily systems in relapsing remitting fashion —similar to syphilis, another spirochetal infection. Lyme is transmitted by the bite of infected ticks, by congenital transmission (from mother to children) and may be transmitted by other means.
If left untreated the infection can spread to joints, the heart, and the nervous system and all organs; this may cause life-threatening complications, including dementia. Early signs of infection include fever, headache, fatigue, and a characteristic skin rash called erythema migrans.
What is the international classification of diseases or ICD?

The ICD is ‘a common global language’ for health professionals. ICD10 was based on approximately 14,400 codes whereas ICD11 represents more than 55,000 codes for disease diagnoses and identifying injuries and causes of death. The ICD are also used to identify health trends, progress and threats and statistics worldwide.

ICD is used by national health systems and program managers, data specialists, policy makers and others who allocate health resources and track national and global health.

From ICD10 to ICD11

Jenna Luché-Thayer, the founder and director of the Ad Hoc Committee for Health Equity in ICD11 Borreliosis Codes, reported,

WHO has recognized Lyme borreliosis to be a ‘disease of consequence’ since the 1990s, but the Lyme codes have remained basically unchanged and many definitions of complications from Lyme disease have also been omitted. [Footnote1], [Footnote 2]

Luché-Thayer reports the Ad Hoc Committee appears to have executed a comprehensive approach that successfully establish new codes for life-threatening complications from Lyme, and improved the definitions of life-threatening complications, including dementia.

This is a major achievement for the global Lyme community because it is the first time in over 25 years that these serious complications have been officially recognized by the WHO.

This is the second change of the ICD11 Lyme dementia definition. The first Lyme dementia definition implied the requirement a Lyme diagnosis required an autopsy. [Footnote 1] [Footnote 2] [Footnote 3]

The first change in the definition states,

 “Dementia due to Lyme disease, a disease caused by an infection with the bacteria Borrelia burgdorferi, with supportive clinical, imaging and laboratory features of the disease without another identifiable cause of cognitive dysfunction.”

 Implementation of this new definition will however, face significant financial, political and cultural challenges.

It appears elder abuse of those living with Lyme and Lyme dementia is also an important public health problem.

CHALLENGES

[1] cultural challenges

Cultural challenges include practices related to the status and respect for of the elderly. These include practices of discrimination against the elderly — including the poor, uneducated, rural groups of elderly and particularly women.

Factors that may increase the risk of elder abuse include:

• ageist stereotypes

• erosion of the bonds between generations of a family

• the distribution of power and material goods within families;

• abandonment of the elderly

• lack of funds to pay for care.

[2] elder abuse

Experts report:

  • Rates of elder abuse are high in the healthcare sector, including medical institutions
  • Elder abuse is predicted to increase as many countries are experiencing rapidly ageing populations.
  • Elder abuse includes the denial of medical care.

[3] no medical consensus regarding the treatment of Lyme

There are two international treatment guidelines for Lyme borreliosis, one is the 2006 guidelines written by the Infectious Diseases Society of America (IDSA) and the second is the 2016 Guidelines written by International Lyme and Associated Disease Society (ILADS).

In the case of Lyme disease, the differential diagnosis of dementia remains largely unpracticed.

[4] big business of dementia

The ‘big business of dementia’ is showing all signs of increase and the spiraling costs show no signs of decreasing. It is reported that decades of research, costly and the largely unaffordable pharmaceutical drugs to treat the manager have largely failed.

Meanwhile, there is expanding evidence that the pathogens that cause Lyme dementia remain ignored  and— despite many of these pathogens can be effectively treated with relatively inexpensive and accessible treatments. 

[5] Increase in persons living with dementia

According to data from World Population Prospects: the 2017 Revision, the number of older persons — those aged 60 years or over — is expected to more than double by 2050 and to more than triple by 2100, rising from 962 million globally in 2017 to 2.1 billion in 2050 and 3.1 billion in 2100.

This data states:

  • Globally, population aged 60 or over is growing faster than all younger age groups.

 

  • In 2017, there are an estimated 962 million people aged 60 or over in the world, comprising 13 per cent of the global population.

 

  • The number of older persons in the world is projected to be 1.4 billion in 2030 and 2.1 billion in 2050, and could rise to 3.1 billion in 2100.

 

  • Globally, the number of persons aged 80 or over is projected to triple by 2050, from 137 million in 2017 to 425 million in 2050.

 

  • In the coming decades many countries are likely to face fiscal and political pressures in relation to public systems of health care, pensions and social protections for a growing older population.”

In summary, it now appears possible that the ICD11’s improved definition for Lyme dementia will offer a solution that improves access to affordable medical care. This may result in the improvement of the longevity, quality of life, productivity and health status of billions of persons across the globe.

Jenna Luché-Thayer. 30+ years working globally on the rights of the marginalized. Former Senior Advisor to the United Nations and the US Government. Director, Ad Hoc Committee for Health Equity in ICD11 Borreliosis Codes. Founder, Global Network on Institutional Discrimination, Inc. —Holding institutions accountable for political and scientific solutions. Email jennaluche@gmail.com

FOOTNOTE 1

Since June 2018 release, the content of the ICD was supposed to be stable.

FOOTNOTE 2

PRESS RELEASE: Ground Breaking Recognition of Lyme Borreliosis in 11th International Classification of Diseases Published on August 1, 2018, author Jenna Luché-Thayer

FOOTNOTE 3

The Ad Hoc Committee for Health Equity in ICD11 Borreliosis Codes is an international, all voluntary, professional committee formed to improve the ICD codes for Lyme and Relapsing Fever borreliosis and address the human rights violations generated by inadequate codes.

____________________

**Comment**

Lyme disease once it gets into the brain can cause or exacerbate many brain diseases. Patients with underlying infection with proper anti-microbial treatment can become completely well or vastly improve.

https://madisonarealymesupportgroup.com/2017/01/04/aluminum-alzheimers-ld/ Within this link you can watch a brief video of Kris Kristofferson, initially diagnosed with Alzheimers but was found to be infected with Lyme disease.

https://madisonarealymesupportgroup.com/2019/03/09/researchers-identify-herpes-1-chlamydia-pneumoniae-several-types-of-spirochaete-as-major-causes-of-alzheimers/

https://madisonarealymesupportgroup.com/2018/03/25/a-brief-history-of-neuroborreliosis-research-dementia-an-inside-look-at-two-researchers/

 

 

 

 

Is A Cell Tower Causing Cancer In School Children?

https://www.brighteon.com/6028326665001

Is A Cell Tower Causing Cancer In School Children

Please click on link above for CBS13 news story of 4 children diagnosed with cancer all attending the same school that has a cell tower on its premise. More than 200 children protested the tower by staying home from school.

Parents hired an electromagnetic radiation specialist who found much higher levels than the district’s experts.  He also stated that it’s not just a cell-tower but it also transmits wireless frequencies.

__________________

https://ehtrust.org/key-issues/cell-phoneswireless/5g-networks-iot-scientific-overview-human-health-risks/  Verizon and Sprint have announced “test cities” for 5G which include Sacramento, Washington DC, Atlanta, Dallas, Miami and New York.

For more:  https://madisonarealymesupportgroup.com/2019/01/16/award-winning-journalist-exposes-wifi-disaster-in-canadian-public-school-that-injured-dozens-of-children-health-alert-on-cell-phones/

https://madisonarealymesupportgroup.com/2019/04/13/study-wi-fi-is-an-important-threat-to-human-health-list-of-scientific-studies/

https://madisonarealymesupportgroup.com/2019/03/13/despite-lack-of-studies-safety-standards-relaxed-ahead-of-5g-emf-health-effects-survey-shows-health-harm-rat-study-shows-microwaves-cause-brain-permeability/

https://madisonarealymesupportgroup.com/2019/03/05/global-5g-will-blanket-the-earth-in-a-mosaic-of-cells/